Log in

NASDAQ:INSM - Insmed Stock Price, Forecast & News

$21.46
-1.23 (-5.42 %)
(As of 01/20/2020 01:45 AM ET)
Today's Range
$21.22
Now: $21.46
$23.02
50-Day Range
$21.46
MA: $23.79
$26.22
52-Week Range
$15.33
Now: $21.46
$33.13
Volume1.35 million shs
Average Volume801,665 shs
Market Capitalization$1.92 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.04
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INSM
CUSIPN/A
Phone908-977-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.84 million
Book Value$2.70 per share

Profitability

Net Income$-324,280,000.00
Net Margins-291.19%

Miscellaneous

Employees373
Market Cap$1.92 billion
Next Earnings Date2/28/2020 (Estimated)
OptionableOptionable

Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks.

Insmed (NASDAQ:INSM) Frequently Asked Questions

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings data on Wednesday, October, 30th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.01. The biopharmaceutical company had revenue of $38.89 million for the quarter, compared to the consensus estimate of $35.89 million. Insmed had a negative return on equity of 114.68% and a negative net margin of 291.19%. During the same period in the previous year, the firm earned ($1.14) earnings per share. View Insmed's Earnings History.

When is Insmed's next earnings date?

Insmed is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for Insmed.

What price target have analysts set for INSM?

7 Wall Street analysts have issued 1 year price targets for Insmed's shares. Their forecasts range from $20.00 to $56.00. On average, they expect Insmed's stock price to reach $39.29 in the next twelve months. This suggests a possible upside of 83.1% from the stock's current price. View Analyst Price Targets for Insmed.

What is the consensus analysts' recommendation for Insmed?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.

What are Wall Street analysts saying about Insmed stock?

Here are some recent quotes from research analysts about Insmed stock:
  • 1. According to Zacks Investment Research, "Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. " (1/2/2020)
  • 2. HC Wainwright analysts commented, "Our price target of $52/share is based on: (a) $51/share, as a 35x multiple of taxed and diluted FY28 GAAP EPS of $7.58 discounted back to and (b) an NPV of $52/share, (discount rate 12.0%, growth rate 2%), with both methods arriving at this target. Risks to our investment thesis and target price include: (1) failure of ALIS in the (2) failure of ALIS to achieve peak commercial revenue estimates in our model due to market size, penetration rates and/or pricing or other limiting factors." (4/9/2019)

Has Insmed been receiving favorable news coverage?

News stories about INSM stock have been trending positive this week, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Insmed earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Insmed.

Are investors shorting Insmed?

Insmed saw a decline in short interest in December. As of December 31st, there was short interest totalling 14,150,000 shares, a decline of 8.9% from the December 15th total of 15,540,000 shares. Based on an average daily trading volume, of 945,200 shares, the days-to-cover ratio is currently 15.0 days. Currently, 16.7% of the company's shares are sold short. View Insmed's Current Options Chain.

Who are some of Insmed's key competitors?

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Intercept Pharmaceuticals (ICPT), Geron (GERN), AbbVie (ABBV), Capstone Turbine (CPST), CHIMERA INVT CO/SH NEW (CIM), Incyte (INCY), Celgene (CELG), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA) and B2Gold (BTG).

Who are Insmed's key executives?

Insmed's management team includes the folowing people:
  • Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50)
  • Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
  • Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)
  • Mr. Roger Adsett, Chief Commercial Officer (Age 50)
  • Dr. Paul D. Streck, Advisor (Age 55)

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $21.46.

How big of a company is Insmed?

Insmed has a market capitalization of $1.92 billion and generates $9.84 million in revenue each year. The biopharmaceutical company earns $-324,280,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis. Insmed employs 373 workers across the globe.View Additional Information About Insmed.

What is Insmed's official website?

The official website for Insmed is http://www.insmed.com/.

How can I contact Insmed?

Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]


MarketBeat Community Rating for Insmed (NASDAQ INSM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  429 (Vote Outperform)
Underperform Votes:  431 (Vote Underperform)
Total Votes:  860
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel